Acute myelogenous leukemia, or AML, remains one of the most aggressive blood cancers. Each year, around 44,000 people in the ...

Cleveland’s WR room is limited after Jerry Jeudy, so should the Browns give Houston a call about John Metchie III?

An international clinical trial co-led by Roswell Park Comprehensive Cancer Center has demonstrated that the investigational ...

Aberrant DNA methylation patterns are a characteristic feature of cancer including myeloid malignancies such as acute myeloid leukemia (AML). The mechanisms behind aberrant DNA methylation have ...

Adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) face significant survival disparities and ...

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for ziftomenib as a treatment for adult patients with relapsed or refractory (R/R) acute myeloid ...

Kura Oncology and Kyowa Kirin have shared details of the phase 2 win for their oral leukemia treatment ziftomenib as the FDA ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Chronic lymphocytic leukemia (CLL) does not typically cause symptoms in its early stages. As it progresses, it can lead to fatigue, lymph node swelling, weakness, frequent infection, and more.

Kura Oncology and Kyowa Kirin submitted data from the KOMET-001 trial, which the agency will review and decide whether to approve the drug by Nov. 30.